Home » Stocks » AnaptysBio

AnaptysBio, Inc. (ANAB)

Stock Price: $20.33 USD 0.17 (0.82%)
Updated Jul 14, 2020 12:30 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 554.41M
Revenue (ttm) 23.00M
Net Income (ttm) -83.52M
Shares Out 27.28M
EPS (ttm) -3.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 14, 2020
Last Price $20.33
Previous Close $20.16
Change ($) 0.17
Change (%) 0.82%
Day's Open 20.16
Day's Range 19.87 - 20.75
Day's Volume 111,012
52-Week Range 10.00 - 56.72

More Stats

Market Cap 554.41M
Enterprise Value 191.86M
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 27.28M
Float 16.08M
EPS (basic) -3.09
EPS (diluted) -3.08
FCF / Share -2.54
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.12M
Short Ratio 11.29
Short % of Float 28.83%
Beta 0.93
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 24.10
PB Ratio 1.53
Revenue 23.00M
Operating Income -92.91M
Net Income -83.52M
Free Cash Flow -69.24M
Net Cash 362.54M
Net Cash / Share 13.29
Gross Margin -397.12%
Operating Margin -403.97%
Profit Margin -363.10%
FCF Margin -301.05%
ROA -12.65%
ROE -19.23%
ROIC -32.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 1
Overweight 0
Hold 5
Underweight 0
Sell 1

Analyst Consensus: Hold

Price Target

$18.67*
(-8.14% downside)
Low
16.0
Current: 20.33
High
28.0
Target: 18.67
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue8.005.0010.0016.6817.5715.84
Revenue Growth60%-50%-40.06%-5.05%10.94%-
Gross Profit8.005.0010.0016.6817.5715.84
Operating Income-107-66.72-28.78-3.03-3.324.87
Net Income-97.34-61.66-30.07-4.26-5.413.53
Shares Outstanding27.0624.6719.782.642.552.48
Earnings Per Share-3.60-2.50-1.52-1.62-2.120.09
Operating Cash Flow-69.52-48.51-19.44-9.03-9.6914.60
Capital Expenditures-0.81-1.06-0.29-0.05-0.24-0.14
Free Cash Flow-70.32-49.57-19.73-9.08-9.9314.46
Cash & Equivalents37442724851.2951.740.00
Total Debt1.387.5714.4313.814.90-
Net Cash / Debt37342023437.4846.840.00
Assets43550932962.1856.28-
Liabilities30.1922.6321.7810091.46-
Book Value405486308-38.25-35.18-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AnaptysBio, Inc.
Country United States
Employees 89
CEO Hamza Suria

Stock Information

Ticker Symbol ANAB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ANAB
IPO Date January 26, 2017

Description

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd.; and collaboration with Celgene Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.